Aurora Cannabis is fully valued following CanniMed acquisition, GMP says

Mar 12 22:03 2018 Print This Article

He likes the Aurora Cannabis (TSX:ACB) pickup of CanniMed (TSX:CMED), but GMP Securities analyst Martin Landry thinks the resultant company doesn’t have much upside from here.

On March 9, Aurora Cannabis announced it was successful in its bid to acquire CanniMed Therapeutics.

“Following the take-up, we will immediately commence with the integration of CanniMed into the Aurora organization and start executing on realizing the strategic synergies we have identified,” said CEO Terry Booth. “Combining two of the leading international cannabis brands creates a company that is exceptionally well positioned to capitalize on the tremendous opportunities in the domestic and international medical markets, as well as the Canadian adult consumer use market, once legalized. We look forward to working closely with our new colleagues to establish Aurora’s Medical Cannabis Centre of Excellence.”

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

Cipher Pharmaceuticals has 157% upside, Echelon Wealth Partners says

New acquisitions from Cardiome Pharma will have positive impact on Cipher Pharmaceuticals (TSX:CPH) going forward, says analyst Douglas Loe of Echelon Wealth Partners, who on Tuesday reiterated his “Buy” rating and 12-month target price of $10.00 for CPH. Earlier this week, dermatology-focused ...

Premier Notley and pipelines—better late than never

Author: Kenneth P. Green The federal carbon-price scheme raises Alberta’s carbon tax to $50 per tonne by 2022. Read more about Premier Notley and pipelines—better late than never Tags:  rachel notley john horgan oil and gas alberta pipeline pipelines kinder morgan pipeline jason k ...

MedReleaf Corp. has a 61 per cent upside, says Canaccord Genuity

MedReleaf Corp’s (TSX:LEAF) new deal to expand into the German medical marijuana market is good news for the company, says Matt Bottomley, analyst with Canaccord Genuity, who on Monday reiterated his “Speculative Buy” rating and $31.00 target price for LEAF. MedReleaf announced on Monday an a ...


PRICE OF OIL NEARS THREE-YEAR HIGH... WTIC Light Crude is trading more than 2% higher today near $65. The weekly bars in Chart 1 (plotted through yesterday) show Light Crude Oil also nearing another three-year high. Brent crude is in a similar situation. Chart 1 shows the United States Oil Fund (U ...

Option Myths and Misconceptions

For those readers who are just beginning their options education journey, I am sure you have been presented with many opinions from other investors and investment professionals alike, regarding the value and risk that options bring to a portfolio. Unfortunately, many myths and misconceptions have a ...

Outlier: Why Bell’s Leadership on Website Blocking Places It at Odds With Telecom Companies Around the World

The Bell website blocking coalition has consistently argued their plan is similar to those found in other countries that have permitted website blocking. As I detailed in my lengthy series on the proposal, it is actually an outlier, since the absence of court orders for blocking puts it at odds wit ...